Cargando…

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial

BACKGROUND: Currently, there are no randomized trials on the effect of antiangiogenic therapy in patients with esophageal squamous cell carcinoma (ESCC). The following study investigated the efficacy and safety of anlotinib in patients with advanced ESCC who were previously treated with chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jing, Xiao, Juxiang, Fang, Wentao, Lu, Ping, Fan, Qingxia, Shu, Yongqian, Feng, Jifeng, Zhang, Shu, Ba, Yi, Zhao, Yang, Liu, Ying, Bai, Chunmei, Bai, Yuxian, Tang, Yong, Song, Yan, He, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940231/ https://www.ncbi.nlm.nih.gov/pubmed/33586360 http://dx.doi.org/10.1002/cam4.3771

Ejemplares similares

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma
por: Song, Yan, et al.
Publicado: (2021)

Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial
por: Huang, Jing, et al.
Publicado: (2019)

Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial
por: Ma, Jianhui, et al.
Publicado: (2020)

Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2)
por: Xu, Jianming, et al.
Publicado: (2022)

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
por: Zhou, Yongjian, et al.
Publicado: (2023)

Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
por: Zhang, Song, et al.
Publicado: (2022)

Survival and prognostic factors of patients with esophageal fistula in advanced esophageal squamous cell carcinoma
por: Guan, Xin, et al.
Publicado: (2020)

Larotinib in patients with advanced and previously treated esophageal squamous cell carcinoma with epidermal growth factor receptor overexpression or amplification: an open-label, multicenter phase 1b study
por: Liu, Rongrui, et al.
Publicado: (2021)

Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
por: Liu, Zhiyong, et al.
Publicado: (2021)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
por: Liu, Tianshu, et al.
Publicado: (2022)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study
por: Xu, Rui-Hua, et al.
Publicado: (2017)

Cost-effectiveness analysis of anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma in China
por: Lin, Jingyang, et al.
Publicado: (2023)

Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma
por: Jiang, Bailing, et al.
Publicado: (2019)

Corrigendum: Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
por: Shi, Jingzhen, et al.
Publicado: (2020)

Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report
por: Chen, Si-Cong, et al.
Publicado: (2023)

Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
por: Chi, Yihebali, et al.
Publicado: (2023)

Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma
por: Bai, Ming, et al.
Publicado: (2022)

Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203)
por: Han, Chun, et al.
Publicado: (2021)

Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III Study
por: Qin, Shukui, et al.
Publicado: (2021)

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
por: Sun, Xin, et al.
Publicado: (2022)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Involvement of DPP3 in modulating oncological features and oxidative stress response in esophageal squamous cell carcinoma
por: Arora, Mohit, et al.
Publicado: (2023)

Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis
por: Zhen, Hongchao, et al.
Publicado: (2023)

Serum DSG2 as a potential biomarker for diagnosis of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma
por: Liu, Yin-Qiao, et al.
Publicado: (2022)

Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma
por: Zhou, Lingxiao, et al.
Publicado: (2023)

ZFPM2-AS1 facilitates cell growth in esophageal squamous cell carcinoma via up-regulating TRAF4
por: Sun, Gaozhong, et al.
Publicado: (2020)

Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
por: Chen, Qing, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma
por: Wang, Jian‐Hua, et al.
Publicado: (2019)

Esophageal squamous cell carcinoma and prognosis in Taiwan
por: Cheng, Ya‐Fu, et al.
Publicado: (2018)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
por: Liu, Ying, et al.
Publicado: (2022)

Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi)
por: Coelingh Bennink, Herjan J.T., et al.
Publicado: (2021)

Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial
por: Lu, Zhihao, et al.
Publicado: (2022)

Investigation of IL-4, IL-10, and HVEM polymorphisms with esophageal squamous cell carcinoma: a case–control study involving 1929 participants
por: Chen, Shuchen, et al.
Publicado: (2020)

A three-gene signature and clinical outcome in esophageal squamous cell carcinoma
por: Sun, Ling-Ling, et al.
Publicado: (2015)

Prognostic impact of MutT homolog‐1 expression on esophageal squamous cell carcinoma
por: Akiyama, Shingo, et al.
Publicado: (2016)

Randomized, double‐blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer
por: Fogelman, David, et al.
Publicado: (2018)

Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China
por: Shan, Xia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ingsll6s5icm80j9g4eq3kt01r